BUZZ1.240%
as of Oct 22
MRNA
GrowthMODERNA INC
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
Close · 3M
+283.85%
Held by 2 AI ETFs
LQAI0.250%
as of Oct 22
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals22
Win rate59% (13/22)
Avg buy return-0.53%
BUZZ · Weight increase · 2d
weight 1.320% → 1.440% (+0.120 pp)·stock up 40.0% in the 30 days before
Oct 20·entry $242.08·now $200.10Fresh
-17.34%
since Oct 20
BUZZ · Weight decrease · 2d
weight 5.050% → 1.320% (-3.730 pp)·stock up 37.9% in the 30 days before
Oct 16·entry $218.01·now $200.10
-8.22%
since Oct 16
BUZZ · Sudden change · 1d
weight 5.050% → 1.360% (-3.690 pp)·stock up 62.4% in the 30 days before
Oct 15·entry $236.50·now $200.10
-15.39%
since Oct 15
BUZZ · Accumulation · 5d
weight 4.190% → 5.050% (+0.860 pp)·stock up 57.4% in the 30 days before
Oct 14·entry $226.30·now $200.10Fresh
-11.58%
since Oct 14
BUZZ · Accumulation · 5d
weight 3.940% → 4.620% (+0.680 pp)·stock up 47.4% in the 30 days before
Oct 13·entry $216.25·now $200.10Fresh
-7.47%
since Oct 13
BUZZ · Weight increase · 3d
weight 3.850% → 4.700% (+0.850 pp)·stock up 64.7% in the 30 days before
Oct 9·entry $225.00·now $200.10Fresh
-11.07%
since Oct 9
BUZZ · Weight increase · 2d
weight 3.850% → 4.170% (+0.320 pp)·stock up 45.3% in the 30 days before
Oct 8·entry $197.00·now $200.10Fresh
+1.57%
since Oct 8
BUZZ · Sudden change · 1d
weight 4.190% → 3.850% (-0.340 pp)·stock up 28.8% in the 30 days before
Oct 6·entry $187.46·now $200.10
+6.74%
since Oct 6
BUZZ · Weight decrease · 3d
weight 4.250% → 3.940% (-0.310 pp)·stock up 26.0% in the 30 days before
Oct 2·entry $190.01·now $200.10
+5.31%
since Oct 2
BUZZ · Accumulation · 5d
weight 3.680% → 3.960% (+0.280 pp)·stock up 22.5% in the 30 days before
Oct 1·entry $188.94·now $200.10Drifting
+5.91%
since Oct 1
BUZZ · Accumulation · 6d
weight 3.530% → 4.040% (+0.510 pp)·stock up 37.2% in the 30 days before
Sep 30·entry $192.57·now $200.10Drifting
+3.91%
since Sep 30
BUZZ · Accumulation · 7d
weight 3.260% → 4.250% (+0.990 pp)·stock up 47.4% in the 30 days before
Sep 29·entry $203.46·now $200.10Fresh
-1.65%
since Sep 29
+1.43%
since Sep 28
+0.61%
since Sep 25
BUZZ · Accumulation · 5d
stock up 22.7% in the 30 days before
Sep 24·entry $194.82·now $200.10Drifting
+2.71%
since Sep 24
BUZZ · Weight increase · 3d
stock up 31.1% in the 30 days before
Sep 23·entry $182.11·now $200.10Drifting
+9.88%
since Sep 23
BUZZ · Weight increase · 2d
stock up 25.8% in the 30 days before
Sep 22·entry $182.56·now $200.10Drifting
+9.61%
since Sep 22
+26.59%
since Sep 17
LQAI · Weight increase · 2d
weight 0.270% → 0.300% (+0.030 pp)·stock up 40.0% in the 30 days before
Oct 20·entry $242.08·now $200.10Fresh
-17.34%
since Oct 20
LQAI · Accumulation · 5d
weight 0.220% → 0.290% (+0.070 pp)·stock up 62.4% in the 30 days before
Oct 15·entry $236.50·now $200.10Fresh
-15.39%
since Oct 15
LQAI · Weight increase · 3d
weight 0.220% → 0.270% (+0.050 pp)·stock up 64.7% in the 30 days before
Oct 9·entry $225.00·now $200.10Fresh
-11.07%
since Oct 9
LQAI · Weight increase · 2d
weight 0.220% → 0.240% (+0.020 pp)·stock up 45.3% in the 30 days before
Oct 8·entry $197.00·now $200.10Fresh
+1.57%
since Oct 8
LQAI · New entry · 1d
weight 0 → 0.250% (new)·stock up 47.4% in the 30 days before
Sep 29·entry $203.46·now $200.10Fresh
-1.65%
since Sep 29
AIUP · Exit · 1d
weight 5.010% → 0 (exited)·stock up 38.2% in the 30 days before
Sep 28·entry $197.28·now $200.10
+1.43%
since Sep 28
AIUP · Weight increase · 3d
stock up 32.9% in the 30 days before
Sep 25·entry $198.88·now $200.10Fresh
+0.61%
since Sep 25
AIUP · Weight increase · 2d
stock up 22.7% in the 30 days before
Sep 24·entry $194.82·now $200.10Drifting
+2.71%
since Sep 24
+15.70%
since Sep 21
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Too hard to callas of Sep 27
AI ETFs like AIUP and BUZZ show strong accumulation and new entries into Moderna, indicating a bullish stance. This contrasts sharply with a Buffett-style value investing framework, which would classify Moderna as 'Too Hard' to analyze due to the unpredictable nature of its future earnings in the biotechnology sector.
- Circle of CompetenceThe biotechnology industry, characterized by high R&D intensity, clinical trial uncertainty, and patent cliffs, makes predicting long-term cash flows challenging for companies like Moderna.
- Economic MoatThis stage is not applicable as the company fails the circle of competence criterion.
- ManagementThis stage is not applicable as the company fails the circle of competence criterion.
- Financial HealthThis stage is not applicable as the company fails the circle of competence criterion.
- Margin of SafetyThis stage is not applicable as the company fails the circle of competence criterion.
Moderna operates in the highly unpredictable biotechnology sector, where future cash flows are difficult to project due to R&D risks and regulatory uncertainties, thus falling outside a traditional value investor's circle of competence. While the company may possess innovative technology, the lack of stable unit economics makes a ten-year earning power prediction unreliable within this framework. Consequently, a comprehensive analysis of its economic moat, management, financials, and intrinsic value cannot be reliably performed.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.